Test ID: DABZO
Drug of Abuse, Benzodiazepine Screen with GC-MS Confirmation, Urine
Secondary ID 
A test code used for billing and in test definitions created prior to November 2011
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Useful For Suggests clinical disorders or settings where the test may be helpful
Confirmation of drug abuse involving benzodiazepines such as alprazolam, chlordiazepoxide, diazepam, flurazepam, lorazepam, and triazolam.
Reflex Tests Lists test(s) that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial test(s)
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| DAUBZ | Drug of Abuse, Benzo Conf, U | Yes | No |
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
If the benzodiazepine screen is > or =200 ng/mL, then benzodiazepine confirmation is performed at an additional charge.
Method Name A short description of the method used to perform the test
DABZO/505337: Enzyme-Multiplied Immunoassay Technique (EMIT)
DAUBZ/500368: Gas Chromatography-Mass Spectrometry (GC-MS)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Aliases Lists additional common names for a test, as an aid in searching
DAU Benzodiazepine Screen, Urine
Drugs of Abuse Benzodiazepine Screen, Urine
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Container/Tube: Plastic, 60-mL urine bottle
Specimen Volume: 20 mL
Collection Instructions:
1. Collect a random urine specimen.
2. No preservative.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Reject Due To Identifies specimen types and conditions that may cause the specimen to be rejected
| Hemolysis | NA |
| Lipemia | NA |
| Icterus | NA |
| Other | NA |
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
| Specimen Type | Temperature | Time |
|---|---|---|
| Urine | Refrigerated (preferred) | 14 days |
| Ambient | 14 days | |
| Frozen | 14 days |
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
The benzodiazepines are central nervous system depressants composed of over 20 parent compounds. The structure of the benzodiazepines varies mainly by substitution of the benzodiazepine ring.
Benzodiazepines are minor tranquilizers, often referred to as anxiolytics (drugs used to control anxiety). Benzodiazepines also are prescribed as muscle relaxants, anesthetic adjuncts, anticonvulsants, and as
treatment for obsessive-compulsive disorders. Due to their wide availability and distribution, a high potential for benzodiazepine abuse exists.
Benzodiazepine mode of action is primarily to enhance gamma-aminobutyric acid (GABA)-mediated transmission. The benzodiazepines are extensively metabolized with half-lives ranging from 2 to 100 hours. Urine level variation is due to individual parent excretion rates as well as metabolic rates.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Negative
EMIT cutoff concentration: 200 ng/mL
Positives are reported with a quantitative GC/MS result.
This report is intended for clinical monitoring and management of patients. It is not intended for use in employment-related drug testing.
Interpretation Provides information to assist in interpretation of the test results
This test screens for the presence of common metabolites of benzodiazepines. The presence of a benzodiazepine metabolite indicates recent use within the past 3 days of the fast-acting drugs such as alprazolam, flurazepam, or triazolam. Chlordiazepoxide and diazepam are cleared very slowly-the presence of their metabolites indicates use sometime within the past 30 to 40 days. This test detects nordiazepam, oxazepam, and temazepam as common metabolites of either chlordiazepoxide or diazepam, lorazepam as the parent drug, hydroxyethylflurorazepam as the metabolite of flurazepam, alpha-hydroxyalprazolam as the metabolite of alprazolam, alpha-hydroxytriazolam as the metabolite of triazolam, 7-aminoclonazepam as the metabolite of clonazepam, and 7-amino-flunitrazepam as the metabolite of flunitrazepam (Rohypnol).
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
No significant cautionary statements.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Porter WF, Moyer TP: Clinical toxicology. In Tietz Textbook of Clinical Chemistry. Second Edition. Edited by CA Burtis, ER Ashwood. Philadelphia, WB Saunders Company, 1994, pp 1155-1235
2. Baselt RC, Cravey RH: Disposition of Toxic Drugs and Chemicals In Man. Third edition. Chicago, IL, Year Book Medical Publishers, 1989
Method Description Describes how the test is performed and provides a method-specific reference
The specimen is screened using an immunoassay procedure with the screening results reported as either positive or negative. The specimen is then analyzed by gas chromatography/mass spectrometry to identify and quantitate any specific benzodiazepine drugs or metabolites present.
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday, Sunday; Varies
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
80101-Screen
G0431-Screen–government payer (if appropriate)
80154-Confirmation (if appropriate)
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
| Result ID | Reporting Name | LOINC Code |
|---|---|---|
| 11572 | Benzodiazepines | 9428-4 |
External
link
PDF
document
Excel
document
Word
document